Synthace Stock
Synthace is a Life Sciences R&D cloud platform that enables experiments to be automated, with the resultant data seamlessly integrated.
Sign up today and learn more about Synthace Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Synthace Stock
Synthace is a R&D cloud platform. Synthace aims to automate experimentation and insight sharing for scientists to share, view, and access progress with cures and therapeutics in one place.
Synthace was founded in 2011 and is headquartered in London, White City. Notable investors include Horizons Ventures, Sofinnova Partners, Amadeus Capital Partners, and Luminous Ventures.
Funding History
| August 2013 | $1.5M |
|---|---|
| January 2015 | $2.9M |
| September 2017 | $10.5M |
| June 2018 | $3.1M |
| December 2018 | $25.4M |
| November 2021 | $6.8M |
| November 2021 | $26.8M |
Management
CEO
Guy Levy-Yurista
Co-founder & Chief Scientific Officer
Markus Gershater
Chief Product Officer
Mathieu Ayel
Press
prnewswire - Dec, 7 2021
IDBS and Synthace announce strategic partnership to streamline bioprocess data managementbusinesscloud - Nov, 17 2021
Synthace raises £26m to automate drug developmentfinsmes - Nov, 16 2021
Synthace Raises $35M in Series C Fundingow - May, 20 2021
Veteran Technology Executive Joins Synthace to Accelerate its Mission to Revolutionize the Life Science Research Marketzpr - Mar, 9 2021
Synthace Appoints Dr. Nick Jurascheck as VP of Engineeringuktech - Nov, 5 2020
Synthace and Ipsen Partner to Accelerate Novel Therapeutic Development Through AutomationEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
